Mustang Bio Inc (MBIO)

[crudeoil24]

That's your PT? .. post a link.

[gregque]

good buy i bought more @ 7.25 pre-market LETS GO MBIO

[Schabblestone]

got in at 7.50 this morning

[gregque]

it has a 18 dollar price target on it crudeoil24

[crudeoil24]

Yes! St. Jude Children's Hospital media dept. covering this development big time!

[gregque]

great news for kids and shareholders IM N

[crudeoil24]

Opening bell surge runs to 11.00+

[doebop]

Added back some 7s

[crudeoil24]

"We've been able to restore a full immune system pretty quickly."

[crudeoil24]

MBIO up 274% @ 9.80 > Mustang Bio's stock soars to near 4-fold gain after deal to commercialize 'bubble boy' disease treatment
7:00 am ET April 18, 2019 (MarketWatch)
Share
Print
Shares of Mustang Bio Inc. (MBIO) blasted off to a near 4-fold gain (up 257%) in premarket trade Thursday, after the biopharmaceutical company said it entered a licensing agreement with St. Jude Children's Research Hospital to develop the lentiviral gene therapy for the treatment of "bubble boy" disease (XSCID) for commercial use. Data from a phase 1/2 clinical trial evaluating the safety and efficacy of a lentiviral vector to transfer a normal copy of the IL2RG gene to bone marrow stem cells in newly diagnosed infants under the age of two with XSCID, showed that bone marrow harvest, busulfan conditioning and cell infusion were well tolerated, all patients cleared previous infections and are growing normally and most patients were discharged from the hospital within one month. "The results have been very good thus far," said Ewelina Mamcarz, assistant member at St. Jude. "We've been able to restore a full immune system pretty quickly." Mustang Bio's stock, which is on track to open at a 1-year high, was down 9.5% year to date through Wednesday. In comparison, the iShares Nasdaq Biotechnology ETF (IBB) has gained 9.0% and the S&P 500 has advanced 15.7%.

-Tomi Kilgore; 415-439-6400; [e-mail]

(END) Dow Jones Newswires

April 18, 2019 07:00 ET (11:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

[Marvy]

Wow, heard about this on the radio the other day

[davidsson10]

"St. Jude licensed the therapy to Mustang Bio Inc., a small biopharmaceutical company that intends to file for global regulatory approval of the gene therapy based mainly on the current data by the end of 2021."

[davidsson10]

https://www.bloomberg.com/news/articles/2019-04-17/-bubble-boys-cured-in-medical-breakthrough-using-gene-therapy

[davidsson10]

https://www.washingtonpost.com/national/health-science/gene-therapy-cures-infants-with-bubble-boy-immune-disease/2019/04/17/ec4b131e-60ff-11e9-bfad-36a7eb36cb60_story.html?utm_term=.3a7566ba493e

[RT2GAIN]

after hours pump?

[Roland Rick Perry]

Studying Now.

Attended an investor presentation lunch with CEO, looks interesting.

[dave7933]

The selling seems to have finished. Great news the past two days. This thing has so much potential it’s unbelievable.

[BTCGoat]

I have been following this stock since IPO and it seems that it is just constant selling every day.

I guess I will wait a few more days/weeks and see if it will turn around.

[dave7933]

A lot of info is on their website. Be sure to look at the video from Fox News regarding how they could address John McCain’s cancer.

[pick]

Besides being a Bio stock, what is it that makes this a good company worth investing in?

Are there interesting new drugs in the pipeline? Clinical trials? Marijuana (CBD) tie-in?

I looked at part of the most recent 10-Q.......they seem to be operating at a loss, which to me is no big surprise.
Do you have any info about how they are raising capital, besides selling stock? Any info regarding the ties to Frontier?

[Pizzaflipper]

Cc

[Pizzaflipper]

V

[dave7933]

This is an exciting Biotech that just went public.